Medicare’s CBD Pilot Program – Business Plan Templates

For the first time, some patients in the US will have a formal pathway for accessing hemp-derived CBD products within a federal healthcare program. A new pilot program from the Centers for Medicare & Medicaid Services (CMS) will allow participating healthcare providers to provide hemp-derived CBD products to patients at no cost to the patient. This is a significant step towards improving US patients’ access for CBD medicine.

CMS CBD Pilot Program

The push to integrate CBD into federally funded healthcare began in December 2025 when President Trump signed Executive Order 14370, “Increasing Medical Marijuana and Cannabidiol Research“. This order laid the groundwork by directing federal agencies to expand research and explore pathways for improving access to full-spectrum CBD products.

From April 1, 2026, under the Substance Access Beneficiary Engagement Initiative (BEI), participating organizations in ACO REACH Model and Enhancing Oncology Model (EOM) programs can obtain up to $500 worth of hemp CBD products per year, per eligible beneficiary, and give them to eligible Medicare beneficiaries enrolled in those programs. From January 1, 2027, the BEI will become available to participants in the Long-term Enhance ACO Design (LEAD) Model as well.

Hemp products are furnished and provided by a qualified physician affiliated with the participating organization to their patient. The providers themselves must cover the cost and procure the products. It should be noted that the beneficiaries cannot submit a Medicare claim for the hemp CBD products.

On the same day the BEI launched, FDA Commissioner Marty Makary issued a memo stating the agency “does not intend to enforce” certain provisions of the Federal Food, Drug, and Cosmetic Act against orally administered, hemp-derived CBD products, provided that the product:

Is manufactured, marketed, and labeled in a manner consistent with the dietary supplement framework.
Is not contaminated.
Is not packaged or labeled in a manner that would be attractive to or marketed for children.
Is provided to a beneficiary through a program of medical items or services payable under Title XVIII of the Social Security Act, under the direction of the patient’s treating physician, in a manner ancillary to the covered items or services furnished under such program.

Eligible Products

Only hemp products meeting the specifications outlined in the table below can be provided to beneficiaries under the BEI.

CBD Type	Hemp-derived with ≤0.3% delta-9 THC
THC Limit	≤3 mg per serving of all THC types (delta-8, delta-10, THCA, etc.)
Product Types	Allowed: Orally administered Excluded: Inhalable products
Source	Cannabinoids must be naturally produced by the cannabis plant (no synthetics)
Testing	Must be third-party tested for potency and contaminants
Patient Eligibility	Medicare beneficiaries in select CMS models; ≥18 years old; not pregnant/breastfeeding; physician-approved
State Law	Product must be legal under applicable state and local laws

Business Implications for Hemp CBD Companies

For hemp CBD producers, the new pilot program creates a federally sanctioned B2B sales channel that did not exist before. Rather than selling directly to consumers, companies can now pitch their products to healthcare providers (physicians and hospitals) participating in the program.

Several companies have already made moves to secure their position in this new market. One hemp product brand, Cornbread Hemp, has announced an exclusive contract with a Group Purchasing Organization (GPO) to serve as the exclusive hemp product supplier for 68,000 healthcare provider locations nationwide under the program. Another company, NuLeaf Naturals, has also stated that it is reaching out to participating organizations to participate in the program as a product supplier.

Businesses looking to participate in this program should first ensure that their products meet the eligibility rules prior to approaching any healthcare provider. This means having up-to-date certificates of analysis from third-party labs for every batch and ensuring that the business complies with all applicable state and local laws. State-by-state information on the regulatory framework for hemp CBD products can be found on our hempcbdbusinessplans website in the US Market section.

When pitching products, the focus should be on safety, consistency, and clinical support. Since the $500 annual product cost per beneficiary will be paid by the provider with no reimbursement from the CMS, the prices charged for hemp CBD products should be structured competitively, as providers will be paying out of pocket. Early movers who establish relationships with participating providers now may gain preferred supplier status if the program expands.

Future Outlook

Industry experts believe that this step towards giving patients more access to hemp-based medicines can lead to the creation of more data demonstrating how CBD can be effective in helping patients. As a result, in the future the range of eligible hemp products and participating programs can expand.

source: hempcbdbusinessplans.com

Shop

'70% ready to go' business plan templates

Launch your hemp CBD business with confidence. Our financial models and business plan templates help you forecast startup and operating costs, project monthly revenue and expenses over seven flexible years - and automatically roll them up into quarterly and annual summaries. Plus: investor-ready pitch deck templates, so you’re prepared when opportunity knocks.